One of the country’s leading hospitals is currently working on an Alzheimer’s vaccine that may be deliverable in the form of a spray.
A team of researchers at Brigham and Women’s Hospital has been working on a nasal spray vaccine that promises to not just slow the progression of symptoms of Alzheimer’s disease in patients who have been diagnosed with the condition, but also possibly even prevent the disease. The team is soon set to start clinical trials of this vaccine. According to a statement by the Ann Romney Centre for Numerological Disease, the clinical trials will focus on whether the vaccine is effective in helping slow down the progression of symptoms in people who have been diagnosed with the condition. The trials will also help confirm if the vaccine can help prevent symptoms of Alzheimer’s disease developing in persons who are at risk of the condition.
The vaccine is based on an ingredient called Protollin, a substance that is currently used in vaccines. The substance serves to stimulate the brain and clear the beta amyloidal plaques that are linked to the development of Alzheimer’s disease. The vaccine will be tested on persons between the ages of 60 and 85 who are currently experiencing early symptoms of Alzheimer’s disease.
This encouraging news comes after the Food and Drug Administration announced the approval of the first drug for Alzheimer’s approved in close to two decades.
Persons with early onset Alzheimer’s disease may be eligible for expedited Social Security disability under the Compassionate Allowances program. This program is especially designed to ensure that potential disability beneficiaries, who suffer from conditions that are chronic or whose symptoms are aggressive, are able to begin receiving their benefits quicker than under the regular process. A claim under the Compassionate Allowances program may be approved in a matter of a few months.